Skip to main content
Pfizer COVID-19 vaccine appointments are available to our patients.
Sign up for Connect today
to schedule your vaccination.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Joint Clinical Trials Office
Explore this Website
Home
About
Toggle About menu options
News
JCTO Contacts
Careers
Our Clinical Trial Locations
Partner with the JCTO
Toggle Partner with the JCTO menu options
JCTO Fees
Open Clinical Trials
Investigators
Patients
Toggle Patients menu options
What is a Clinical Trial?
Frequently Asked Questions
Clinical Trial Questions to Ask Your Healthcare Team
Clinical Trials: Common Terms to Know
Understanding Clinical Trials and How They Work
Understanding Clinical Trials - In Spanish | En Español
Weill Cornell Medicine
Care
Discover
Teach
Home
About
Open Clinical Trials
Investigators
Patients
Home
Clinical Trials
An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure
Study Status:
Open to Enrollment
Primary Investigator:
Date:
September 4, 2024
A Study to Evaluate the Safety and Effectiveness of the Standard of Care Diversion, Diverting Ileostomy, Following Low Anterior Resection
Study Status:
Open to Enrollment
Primary Investigator:
Date:
September 4, 2024
Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date:
September 4, 2024
Local Methotrexate Injections for the Treatment of Nail Psoriasis
Study Status:
Open to Enrollment
Primary Investigator:
Date:
September 12, 2024
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Study Status:
Open to Enrollment
Primary Investigator:
Date:
October 2, 2024
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment
Study Status:
Open to Enrollment
Primary Investigator:
Date:
October 2, 2024
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date:
October 2, 2024
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab
Study Status:
Open to Enrollment
Primary Investigator:
Date:
October 2, 2024
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date:
October 29, 2024
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
November 1, 2024
« first
‹ previous
…
20
21
22
23
24
25
(current)
26
27
28
next ›
last »